Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis
- 1 November 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (11), 3082-3084
- https://doi.org/10.1038/s41375-020-0905-y
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative StudyLeukemia, 2020
- Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631Journal of Clinical Oncology, 2017
- Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumabBlood, 2017
- The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemiaBlood, 2016
- Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid plus chemotherapy or with all-transretinoic acid plus arsenic trioxideLeukemia & Lymphoma, 2014
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaNew England Journal of Medicine, 2013
- Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemiaCancer, 2012
- All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)Blood, 2012